Nestorov I A, Aarons L J, Arundel P A, Rowland M
Central Laboratory of Biomedical Engineering, Acad. G. Bonchev Str., Sofia, Bulgaria.
J Pharmacokinet Biopharm. 1998 Feb;26(1):21-46. doi: 10.1023/a:1023272707390.
Lumping is a common pragmatic approach aimed at the reduction of whole-body physiologically based pharmacokinetic (PBPK) model dimensionality and complexity. Incorrect lumping is equivalent to model misspecification with all the negative consequences to the subsequent model implementation. Proper lumping should guarantee that no useful information about the kinetics of the underlying processes is lost. To enforce this guarantee, formal standard lumping procedures and techniques need to be defined and implemented. This study examines the lumping process from a system theory point of view, which provides a formal basis for the derivation of principles and standard procedures of lumping. The lumping principle in PBPK modeling is defined as follows: Only tissues with identical model specification, and occupying identical positions in the system structure should be lumped together at each lumping iteration. In order to lump together parallel tissues, they should have similar or close time constants. In order to lump together serial tissues, they should equilibrate very rapidly with one another. The lumping procedure should include the following stages: (i) tissue specification conversion (when tissues with different model specifications are to be lumped together); (ii) classification of the tissues into classes with significantly different kinetics, according to the basic principle of lumping above; (iii) calculation of the parameters of the lumped compartments; (iv) simulation of the lumped system; (v) lumping of the experimental data; and (vi) verification of the lumped model. The use of the lumping principles and procedures to be adopted is illustrated with an example of a commonly implemented whole-body physiologically based pharmacokinetic model structure to characterize the pharmacokinetics of a homologous series of barbiturates in the rat.
集总是一种常见的实用方法,旨在降低基于生理学的全身药代动力学(PBPK)模型的维度和复杂性。错误的集总等同于模型设定错误,会给后续模型实施带来所有负面后果。正确的集总应确保不会丢失有关潜在过程动力学的任何有用信息。为了实现这一保证,需要定义和实施正式的标准集总程序和技术。本研究从系统理论的角度审视集总过程,为集总原理和标准程序的推导提供了正式基础。PBPK建模中的集总原理定义如下:在每次集总迭代中,只有具有相同模型规格且在系统结构中占据相同位置的组织才能被集总在一起。为了将平行组织集总在一起,它们应具有相似或相近的时间常数。为了将串联组织集总在一起,它们应彼此非常快速地达到平衡。集总程序应包括以下阶段:(i)组织规格转换(当具有不同模型规格的组织要集总在一起时);(ii)根据上述集总基本原理,将组织分类为具有显著不同动力学的类别;(iii)计算集总隔室的参数;(iv)模拟集总系统;(v)集总实验数据;以及(vi)验证集总模型。通过一个常用的基于生理学的全身药代动力学模型结构的例子,说明了所采用的集总原理和程序的应用,以表征大鼠体内一系列同源巴比妥类药物的药代动力学。